- KR₩332bn
- KR₩633bn
- KR₩809bn
Brief: Dong-A St To Cancel 5 Billion Won Worth Of Own Shares
Brief: Dong-A St Q4 Operating Loss 554 Million Won
Brief: Dong-A St Q2 Operating Profit 4 Billion Won, Down 43.4% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 7 Billion Won, Up 854% From Year Earlier
Brief: Dong-A St Q4 Operating Profit 4.8 Billion Won, Up 15% From Year Earlier
Brief: Dong-A St Q2 Operating Profit 7 Billion Won, Down 19% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 735 Million Won, Down 89% From Year Earlier
Brief: Dong-A St Q4 Operating Profit 7 Billion Won, Up 75% From Year Earlier
Brief: FDA Accepts For Review BLA For Dmb-3115 Of Dong-A St, A Proposed Biosimilar To Stelara®
Brief: Dong-A St Q3 Operating Profit 13 Billion Won, Down 7.7% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 6.7 Billion Won, Down 15% From Year Earlier
Brief: Dong-A St Co To Acquire 2.5 Billion Won Worth Of Own Shares
Brief: Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 And Stelara In Global Phase III
Brief: Dong-A St Co Completes Global 3Rd Phase Clinical Trial For Its Stelara Biosimilar
Brief: Dong-A St Q3 Operating Profit 14 Billion Won, Up 22% From Year Earlier
Brief: NeuroBo Pharma And Dong-A ST Partner To License And Develop Dong-A's Cardio-Metabolic Therapies
NeuroBo Pharma surges after gaining rights to liver disease drugs
Brief: Dong-A ST to pay annual cash dividend as 500 won/share
Brief: Core Logic to buy 98.96 pct stake in M.I.TECH for 30 bln won